Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 9:29 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 117 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: electroporation therapy Clear all

Conditions: HCC
Interventions: GNOS-PV02 + INO-9012 delivered by intradermal injection, followed by electroporation, Electroporation Device, INO-9012; Biological · Device
Lead sponsor: Geneos Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 8
States / cities: Atlanta, Georgia • New Orleans, Louisiana • Baltimore, Maryland + 4 more

Conditions: Cancer
Interventions: MedPulser Electroporation with bleomycin; Combination Product
Lead sponsor: Inovio Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: San Diego, California

Conditions: Coronavirus Infection
Interventions: INO-4800, CELLECTRA® 2000; Drug · Device
Lead sponsor: Inovio Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 3
States / cities: Lexington, Kentucky • Kansas City, Missouri • Philadelphia, Pennsylvania

Conditions: Prostate Cancer
Interventions: cryotherapy; Device
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2039
U.S. locations: 1
States / cities: New York, New York

Conditions: ER-Negative PR-Negative HER2-Negative Breast Cancer
Interventions: IT-pIL12-EP; Biological
Lead sponsor: OncoSec Medical Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Stanford, California

Conditions: HIV Infections
Interventions: PENNVAX-B, IL-12 DNA plasmids; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 3
States / cities: Rochester, New York • Philadelphia, Pennsylvania • Nashville, Tennessee

Conditions: HPV Infection
Interventions: pBI-11 (3 doses), pBI-11 (1 dose), Placebo (2 doses); Biological
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Female only
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Birmingham, Alabama • Baltimore, Maryland

Conditions: Pancreatic Cancer
Interventions: IRE + intratumoral mitazalimab (CD40 antibody) injection, NanoKnife; Drug · Device
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 1
States / cities: La Jolla, California

Conditions: AF - Atrial Fibrillation
Interventions: Pulse Field Ablation; Procedure
Lead sponsor: Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute); Other
Eligibility: 18 Years to 89 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: HIV Infections
Interventions: TriGrid™ Delivery System, conventional intramuscular injection; Device
Lead sponsor: Rockefeller University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Atrial Fibrillation Paroxysmal
Interventions: Farapulse PFA, Pulmonary Vein Isolation alone, Farapulse PFA, Pulmonary Vein Isolation and Left atrial Posterior Wall Isolation; Device
Lead sponsor: Jorge Romero; Other
Eligibility: 21 Years to 90 Years
Enrollment: 198 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 18
States / cities: Birmingham, Alabama • Washington D.C., District of Columbia • Jacksonville, Florida + 13 more

Conditions: Atrial Fibrillation
Interventions: Pulsed Field Ablation (PFA); Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 80 Years
Enrollment: 442 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 6
States / cities: Jonesboro, Arkansas • Boston, Massachusetts • New York, New York + 1 more

Conditions: Healthy
Interventions: INO-3401 + EP; Biological
Lead sponsor: Inovio Pharmaceuticals; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: Overland Park, Kansas • Rockville, Maryland

Conditions: HIV Infections
Interventions: HIV-MAG vaccine, IL-12 pDNA adjuvant, VSV HIV gag vaccine, Placebo, Ichor Medical Systems TriGrid™ Delivery System (TDS) electroporation (EP) device; Biological · Device
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2016
U.S. locations: 5
States / cities: New York, New York • Rochester, New York • Philadelphia, Pennsylvania + 1 more

Conditions: Malignant Melanoma
Interventions: IL-12p DNA, Intratumoral Electroporation; Biological · Procedure
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Locally Advanced Pancreatic Adenocarcinoma
Interventions: 1.0% IP-001 for injection, Irreversible Electroporation; Drug · Procedure
Lead sponsor: Robert C. Martin; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Head and Neck Squamous Cell Carcinoma
Interventions: Tavokinogene Telseplasmid (tavo), OncoSec Medical System (OMS); Biological · Device
Lead sponsor: OncoSec Medical Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: San Francisco, California • Chicago, Illinois

Conditions: Hepatitis B
Interventions: INO-1800, INO-9112, Nucleos(t)ide Analogue Treatment; Biological · Drug
Lead sponsor: Inovio Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 7
States / cities: San Diego, California • Miami, Florida • Manhasset, New York + 4 more

Conditions: Melanoma
Interventions: Tavokinogene Telseplasmid (tavo), OncoSec Medical System (OMS); Biological · Device
Lead sponsor: OncoSec Medical Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 6
States / cities: San Francisco, California • Santa Monica, California • Denver, Colorado + 3 more

Conditions: BRCA1/2 Mutation
Interventions: INO-5401, INO-9012, Cellectra 2000; Drug · Device
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Prostate Cancer
Interventions: Focal Therapy; Procedure
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older · Male only
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2034
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Persistent Atrial Fibrillation, Paroxysmal Atrial Fibrillation, Long-standing Persistent Atrial Fibrillation
Interventions: Farapulse Catheter System, Low-dose Colchicine; Device · Drug
Lead sponsor: Vivek Reddy; Other
Eligibility: 18 Years and older
Enrollment: 275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 9
States / cities: Jonesboro, Arkansas • Ventura, California • Naples, Florida + 5 more

Conditions: Metastatic Castration-resistant Prostate Cancer
Interventions: NKTR-214 (Cohort A), Nivolumab (Cohort A, B and C), Stereotactic body radiation therapy (SBRT) (Cohort B), CDX-301 (Cohort B and C), Poly-ICLC (Cohort B), INO-5151 (Cohort C), Cellectra 2000; Drug · Radiation · Device
Lead sponsor: Parker Institute for Cancer Immunotherapy; Other
Eligibility: 18 Years and older · Male only
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 6
States / cities: Los Angeles, California • San Francisco, California • New York, New York + 2 more

Conditions: Prostate Cancer
Interventions: IRE & MRgRT; Device
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 99 Years · Male only
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Personalized Neoantigen Vaccine Plus IL-12 (INO-9012) Versus Active Surveillance in Subjects With High-Risk HCC

Study Using the MedPulser Electroporation System With Bleomycin to Treat Cutaneous and Subcutaneous Cancer

Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers

Ablative Therapy in the Management of Prostate Cancer

Evaluation of Pharmacodynamic Effects of IT-pIL12-EP in Patients With TNBC

Safety of and Immune Response to the PENNVAX-B DNA Vaccine With and Without IL-12 in HIV-uninfected Adults

Assessing Administration of pBI-11 Via Electroporation for the Treatment of Patients With HPV16/18+

Intra-tumoral Mitazalimab (CD40 Antibody) With Irreversible Electroporation (IRE) in Locally Advanced Pancreas Cancer

Comparison of Two Pulse Field Ablation Systems for AF Ablation

Study of a Potential Preventive Vaccine Against HIV in Healthy Volunteers

Posterior Wall Substrate Modification Using Irreversible Electroporation for Paroxysmal Atrial Fibrillation

Safety and Effectiveness of Pulmonary Vein isOLation And posterioR Wall Ablation wIth pulSed Field Energy in Patients With Paroxysmal and Persistent AF

A Follow-On Study With an H5 Influenza Vaccine for Subjects Who Participated in Study FLU-001

Evaluating the Safety of and Immune Response to HIV-MAG DNA Vaccine With or Without Plasmid IL-12 Adjuvant Delivered Intramuscularly Via Electroporation Followed by VSV-gag HIV Vaccine Boost in Healthy, HIV-Uninfected Adults

Phase I Trial of Intratumoral pIL-12 Electroporation in Malignant Melanoma

Immunotherapy and Irreversible Electroporation (IRE) in the Treatment of Locally Advanced Pancreatic Adenocarcinoma

Trial of pIL-12 Electroporation in Squamous Cell Carcinoma of the Head and Neck (IL12HNSCC)

Phase I Study of INO-1800 With or Without INO-9112 + EP in Chronic Hepatitis B Subjects

Trial of pIL-12 Electroporation Malignant Melanoma

INO 5401 Vaccination in BRCA1/2 Mutation Carriers

Focal Therapy for Localized Prostate Cancer

Pragmatic Evaluation of a Pentaspline Pulsed Field Ablation System to Treat Atrial Fibrillation and Related Arrhythmias

Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations

Radiation Therapy and IRreversible Electroporation for Intermediate Risk Prostate Cancer (RTIRE)